BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sidhu A, Verma G, Humar A, Kumar D. Outcome of latent tuberculosis infection in solid organ transplant recipients over a 10-year period. Transplantation. 2014;98:671-675. [PMID: 24825525 DOI: 10.1097/tp.0000000000000133] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Maphalle LNF, Michniak-kohn BB, Ogunrombi MO, Adeleke OA. Pediatric Tuberculosis Management: A Global Challenge or Breakthrough? Children 2022;9:1120. [DOI: 10.3390/children9081120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lauar ID, Faria LC, Romanelli RMC, Clemente WT. Latent tuberculosis: Risk factors, screening and treatment in liver transplantation recipients from an endemic area. World J Transplant 2021; 11(12): 512-522 [DOI: 10.5500/wjt.v11.i12.512] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
3 Shu CC, Tsai MK, Lin SW, Wang JY, Yu CJ, Lee CY. Latent Tuberculosis Infection Increases in Kidney Transplantation Recipients Compared With Transplantation Candidates: A Neglected Perspective in Tuberculosis Control. Clin Infect Dis 2020;71:914-23. [PMID: 32620949 DOI: 10.1093/cid/ciz851] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Yang A, Shi J, Luo Y, Ye Y, Tan Y, Huang H, Zhao Y. Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis. Sci Rep 2019;9:20402. [PMID: 31892702 DOI: 10.1038/s41598-019-56013-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
5 Silva JT, San-Juan R, Fernández-Ruiz M, Aguado JM. Fluoroquinolones for the treatment of latent Mycobacterium tuberculosis infection in liver transplantation. World J Gastroenterol 2019; 25(26): 3291-3298 [PMID: 31341356 DOI: 10.3748/wjg.v25.i26.3291] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Almufty HB, Abdulrahman IS, Merza MA. Latent Tuberculosis Infection among Healthcare Workers in Duhok Province: From Screening to Prophylactic Treatment. Trop Med Infect Dis 2019;4:E85. [PMID: 31126022 DOI: 10.3390/tropicalmed4020085] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
7 Philley JV, Griffith DE. Antimycobacterial Consideration in Transplantation Including Drug Non-susceptibility and Resistance: Tuberculosis and Nontuberculous Mycobacterial Disease. Principles and Practice of Transplant Infectious Diseases 2019. [DOI: 10.1007/978-1-4939-9034-4_56] [Reference Citation Analysis]
8 Chascsa DM, Vargas HE. The gastroenterologist's guide to management of the post-liver transplant patient. Am J Gastroenterol 2018;113:819-28. [PMID: 29748558 DOI: 10.1038/s41395-018-0049-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
9 Pennington KM, Kennedy CC, Chandra S, Lauzardo M, Brito MO, Griffith DE, Seaworth BJ, Escalante P. Management and diagnosis of tuberculosis in solid organ transplant candidates and recipients: Expert survey and updated review. J Clin Tuberc Other Mycobact Dis 2018;11:37-46. [PMID: 31720390 DOI: 10.1016/j.jctube.2018.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
10 Basera TJ, Ncayiyana J, Engel ME. Prevalence and risk factors of latent tuberculosis infection in Africa: a systematic review and meta-analysis protocol. BMJ Open 2017;7:e012636. [PMID: 28720611 DOI: 10.1136/bmjopen-2016-012636] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
11 Solomon E. Owumi, Michael A. Gbadegesin, Fisayo A. Olotu, Oyeronke A. Odunola. Isoniazid Induced Toxicities and Idiosyncratic Responses in Male Albino Wistar Rats. J Can Res Updates 2017;6. [DOI: 10.6000/1929-2279.2017.06.02.2] [Reference Citation Analysis]
12 Knoll BM, Nog R, Wu Y, Dhand A. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates. Infection. 2017;45:335-339. [PMID: 28276008 DOI: 10.1007/s15010-017-1004-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
13 Kiazyk S, Ball TB. Latent tuberculosis infection: An overview. Can Commun Dis Rep 2017;43:62-6. [PMID: 29770066 DOI: 10.14745/ccdr.v43i34a01] [Cited by in Crossref: 51] [Cited by in F6Publishing: 57] [Article Influence: 8.5] [Reference Citation Analysis]
14 Mah A, Wright A. Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation. Curr Infect Dis Rep. 2016;18:4. [PMID: 26743200 DOI: 10.1007/s11908-015-0514-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
15 Liu J, Yan J, Wan Q, Ye Q, Huang Y. The risk factors for tuberculosis in liver or kidney transplant recipients. BMC Infect Dis 2014;14:387. [PMID: 25015108 DOI: 10.1186/1471-2334-14-387] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]